GLP-1 Therapy and Mental Health: What the Research Shows

The relationship between GLP-1 therapy and mental health has been an area of active research and regulatory attention. Concerns about suicidality prompted an FDA investigation, while other research has suggested potential benefits for depression and anxiety. Prescribers need to understand both sides of this picture.

In 2023, the European Medicines Agency (EMA) and the FDA announced they were investigating reports of suicidal thoughts and self-harm in patients taking GLP-1 receptor agonists. This investigation was triggered by reports submitted to regulatory databases.

Both the EMA and FDA conducted thorough reviews of available data:

FDA review (2024): The FDA reviewed data from clinical trials, observational studies, and spontaneous adverse event reports. The conclusion: the available evidence does not support a causal relationship between GLP-1 agonists and suicidal ideation or behavior.

EMA review (2024): The EMA reached a similar conclusion — the available evidence does not support a causal link between GLP-1 agonists and suicidality.

Large observational studies: Multiple large observational studies have found that GLP-1 therapy is associated with reduced rates of depression and suicidality compared to other weight loss interventions or no treatment.

The initial reports of suicidality were likely confounded by:

• Obesity and depression: Obesity is a major risk factor for depression and suicidality. Patients on GLP-1 therapy are, by definition, obese — so some baseline rate of depression and suicidality is expected.
• Weight loss and mood: Rapid weight loss can sometimes be associated with mood changes, independent of the medication.
• Reporting bias: Adverse event databases capture reports without establishing causation.

The FDA has not added a suicidality warning to GLP-1 agonist labeling. Prescribers should monitor for mood changes but should not be deterred from prescribing based on the initial concern.

While the suicidality concern has been largely resolved, research has identified potential mental health benefits of GLP-1 therapy:

Multiple studies have found that GLP-1 therapy is associated with improvements in depression symptoms:

Mechanism: GLP-1 receptors are expressed in brain regions involved in mood regulation, including the hippocampus and prefrontal cortex. GLP-1 agonism may have direct antidepressant effects.

Weight loss effects: Weight loss itself is associated with improvements in depression and self-esteem. The significant weight loss produced by GLP-1 therapy may improve mood through this pathway.

2024 meta-analysis: A meta-analysis of 12 studies found that GLP-1 therapy was associated with significant improvements in depression scores compared to placebo or comparator treatments.

Some research has found improvements in anxiety symptoms with GLP-1 therapy, though the evidence is less robust than for depression.

GLP-1 receptors are expressed throughout the brain, and GLP-1 agonism has been studied for potential neuroprotective effects. Some research suggests GLP-1 therapy may improve cognitive function, particularly in patients with metabolic syndrome or type 2 diabetes.

Multiple clinical trials have documented significant improvements in health-related quality of life with GLP-1 therapy, including improvements in physical functioning, vitality, and mental health domains.

Before starting GLP-1 therapy, assess:

• Current depression or anxiety symptoms
• History of psychiatric conditions
• Current psychiatric medications
• Suicidal ideation (use validated screening tools like PHQ-9)

Monitor for:

• Mood changes (positive or negative)
• New or worsening depression or anxiety
• Any suicidal ideation

"Some patients report improvements in mood and energy with GLP-1 therapy, likely related to weight loss and the medication's effects on the brain. We'll monitor your mood during treatment. If you notice any significant mood changes — positive or negative — let me know."

Patients with pre-existing depression, anxiety, or other mental health conditions can receive GLP-1 therapy. Coordinate with their mental health provider and monitor more closely.

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should use clinical judgment and monitor patients for mental health changes during GLP-1 therapy.